1
|
Capogna E, Sørensen Ø, Watne LO, Roe J, Strømstad M, Idland AV, Halaas NB, Blennow K, Zetterberg H, Walhovd KB, Fjell AM, Vidal-Piñeiro D. Subtypes of brain change in aging and their associations with cognition and Alzheimer's disease biomarkers. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.03.04.583291. [PMID: 38496633 PMCID: PMC10942348 DOI: 10.1101/2024.03.04.583291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2024]
Abstract
Structural brain changes underly cognitive changes in older age and contribute to inter-individual variability in cognition. Here, we assessed how changes in cortical thickness, surface area, and subcortical volume, are related to cognitive change in cognitively unimpaired older adults using structural magnetic resonance imaging (MRI) data-driven clustering. Specifically, we tested (1) which brain structural changes over time predict cognitive change in older age (2) whether these are associated with core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers phosphorylated tau (p-tau) and amyloid-β (Aβ42), and (3) the degree of overlap between clusters derived from different structural features. In total 1899 cognitively healthy older adults (50 - 93 years) were followed up to 16 years with neuropsychological and structural MRI assessments, a subsample of which (n = 612) had CSF p-tau and Aβ42 measurements. We applied Monte-Carlo Reference-based Consensus clustering to identify subgroups of older adults based on structural brain change patterns over time. Four clusters for each brain feature were identified, representing the degree of longitudinal brain decline. Each brain feature provided a unique contribution to brain aging as clusters were largely independent across modalities. Cognitive change and baseline cognition were best predicted by cortical area change, whereas higher levels of p-tau and Aβ42 were associated with changes in subcortical volume. These results provide insights into the link between changes in brain morphology and cognition, which may translate to a better understanding of different aging trajectories.
Collapse
Affiliation(s)
- Elettra Capogna
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
| | - Øystein Sørensen
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
| | - Leiv Otto Watne
- Department of Geriatric Medicine, Akershus University Hospital, Lørenskog, Norway
- Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway
| | - James Roe
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
| | - Marie Strømstad
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
| | - Ane Victoria Idland
- Oslo Delirium Research Group, Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway
| | - Nathalie Bodd Halaas
- Oslo Delirium Research Group, Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway
- Institute of Clinical Medicine, Campus UllevÅl, University of Oslo, Oslo, Norway
| | - Kaj Blennow
- Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
- Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China
| | - Henrik Zetterberg
- Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
- UK Dementia Research Institute at UCL, London, UK
- Hong Center for Neurodegenerative Diseases, Hong Kong, China
- Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
| | - Kristine Beate Walhovd
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
- Computational Radiology and Artificial Intelligence, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
| | - Anders Martin Fjell
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
- Computational Radiology and Artificial Intelligence, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
| | - Didac Vidal-Piñeiro
- Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, 0373 Oslo, Norway
| |
Collapse
|
2
|
Trombetta BA, Wu C, Kuo E, de Geus MB, Dodge HH, Carlyle BC, Kivisäkk P, Arnold SE. Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease. ALZHEIMER'S & DEMENTIA (NEW YORK, N. Y.) 2024; 10:e12440. [PMID: 38356471 PMCID: PMC10865489 DOI: 10.1002/trc2.12440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 11/20/2023] [Accepted: 11/22/2023] [Indexed: 02/16/2024]
Abstract
INTRODUCTION While Alzheimer's disease (AD) is defined by amyloid-β plaques and tau tangles in the brain, it is evident that many other pathophysiological processes such as inflammation, neurovascular dysfunction, oxidative stress, and metabolic derangements also contribute to the disease process and that varying contributions of these pathways may reflect the heterogeneity of AD. Here, we used a previously validated panel of cerebrospinal fluid (CSF) biomarkers to explore the degree to which different pathophysiological domains are dysregulated in AD and how they relate to each other. METHODS Twenty-five CSF biomarkers were analyzed in individuals with a clinical diagnosis of AD verified by positive CSF AD biomarkers (AD, n = 54) and cognitively unimpaired controls negative for CSF AD biomarkers (CU-N, n = 26) using commercial single- and multi-plex immunoassays. RESULTS We noted that while AD was associated with increased levels of only three biomarkers (MMP-10, FABP3, and 8OHdG) on a group level, half of all AD participants had increased levels of biomarkers belonging to at least two pathophysiological domains reflecting the diversity in AD. LASSO modeling showed that a panel of FABP3, 24OHC, MMP-10, MMP-2, and 8OHdG constituted the most relevant and minimally correlated set of variables differentiating AD from CU-N. Interestingly, factor analysis showed that two markers of metabolism and oxidative stress (24OHC and 8OHdG) contributed independent information separate from MMP-10 and FABP3 suggestive of two independent pathophysiological pathways in AD, one reflecting neurodegeneration and vascular pathology, and the other associated with metabolism and oxidative stress. DISCUSSION Better understanding of the heterogeneity among individuals with AD and the different contributions of pathophysiological processes besides amyloid-β and tau will be crucial for optimizing personalized treatment strategies. Highlights A panel of 25 highly validated biomarker assays were measured in CSF.MMP10, FABP3, and 8OHdG were increased in AD in univariate analysis.Many individuals with AD had increased levels of more than one biomarker.Markers of metabolism and oxidative stress contributed to an AD multianalyte profile.Assessing multiple biomarker domains is important to understand disease heterogeneity.
Collapse
Affiliation(s)
- Bianca A. Trombetta
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Chao‐Yi Wu
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Evan Kuo
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Matthijs B. de Geus
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Department of Cell & Chemical BiologyLeiden University Medical CenterLeidenThe Netherlands
| | - Hiroko H. Dodge
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Becky C. Carlyle
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Department of Physiology, Anatomy and GeneticsUniversity of OxfordOxfordUK
- Kavli Institute for Nanoscience DiscoveryUniversity of OxfordOxfordUK
| | - Pia Kivisäkk
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Steven E. Arnold
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| |
Collapse
|
3
|
Shaji S, Palanisamy R, Swaminathan R. Structural irregularities in MR corpus callosal images and their association with cerebrospinal fluid biomarkers in Mild Cognitive Impairments. Neurosci Lett 2023; 810:137329. [PMID: 37301466 DOI: 10.1016/j.neulet.2023.137329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2023] [Revised: 05/15/2023] [Accepted: 06/05/2023] [Indexed: 06/12/2023]
Abstract
In this study, irregularity measures from MR images of corpus callosal brain structures in healthy and Mild Cognitive Impairment (MCI) conditions are extracted and their association with Cerebrospinal Fluid (CSF) biomarkers are analyzed. For this, MR images of healthy controls, Early MCI (EMCI) and Late MCI (LMCI) subjects are considered from a public database. The considered images are preprocessed and corpus callosal structure is segmented. Structural irregularity measures are extracted from the segmented regions using Fourier analysis. Statistical tests are performed to identify the significant features which can characterize the MCI stages. Association of these measures with CSF amyloid beta and tau concentrations are further investigated. Results demonstrate that Fourier spectral analysis is able to characterize the non-periodic variations in the corpus callosal structures of healthy, EMCI and LMCI MR images. The callosal irregularity measures increase as the disease progresses from healthy to LMCI. Phosphorylated tau concentrations in CSF demonstrate a positive correlation with irregularity measures across the diagnostic groups. Significant association of callosal measures and amyloid beta levels are found to be absent in MCI stages. As corpus callosal structural irregularities due to early MCI condition and their association with CSF markers remain uncharacterized in the literature, this study seems to be clinically significant for the timely intervention of pre-symptomatic MCI stages.
Collapse
Affiliation(s)
- Sreelakshmi Shaji
- Non-Invasive Imaging and Diagnostic Laboratory, Biomedical Engineering Group, Department of Applied Mechanics, Indian Institute of Technology Madras, Chennai, India.
| | - Rohini Palanisamy
- Indian Institute of Information Technology, Design and Manufacturing, Kancheepuram, Chennai, India.
| | - Ramakrishnan Swaminathan
- Non-Invasive Imaging and Diagnostic Laboratory, Biomedical Engineering Group, Department of Applied Mechanics, Indian Institute of Technology Madras, Chennai, India.
| |
Collapse
|
4
|
Controlling the Impact of Helicobacter pylori-Related Hyperhomocysteinemia on Neurodegeneration. Medicina (B Aires) 2023; 59:medicina59030504. [PMID: 36984505 PMCID: PMC10056452 DOI: 10.3390/medicina59030504] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Revised: 02/27/2023] [Accepted: 02/28/2023] [Indexed: 03/08/2023] Open
Abstract
Helicobacter pylori infection consists a high global burden affecting more than 50% of the world’s population. It is implicated, beyond substantiated local gastric pathologies, i.e., peptic ulcers and gastric cancer, in the pathophysiology of several neurodegenerative disorders, mainly by inducing hyperhomocysteinemia-related brain cortical thinning (BCT). BCT has been advocated as a possible biomarker associated with neurodegenerative central nervous system disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and/or glaucoma, termed as “ocular Alzheimer’s disease”. According to the infection hypothesis in relation to neurodegeneration, Helicobacter pylori as non-commensal gut microbiome has been advocated as trigger and/or mediator of neurodegenerative diseases, such as the development of Alzheimer’s disease. Among others, Helicobacter pylori-related inflammatory mediators, defensins, autophagy, vitamin D, dietary factors, role of probiotics, and some pathogenetic considerations including relevant involved genes are discussed within this opinion article. In conclusion, by controlling the impact of Helicobacter pylori-related hyperhomocysteinemia on neurodegenerative disorders might offer benefits, and additional research is warranted to clarify this crucial topic currently representing a major worldwide burden.
Collapse
|
5
|
Dhiman K, Villemagne VL, Fowler C, Bourgeat P, Li QX, Collins S, Rowe CC, Masters CL, Ames D, Blennow K, Zetterberg H, Martins RN, Gupta V. Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2022; 14:e12377. [PMID: 36479019 PMCID: PMC9719998 DOI: 10.1002/dad2.12377] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 10/05/2022] [Accepted: 10/19/2022] [Indexed: 12/12/2022]
Abstract
Introduction Fatty acid-binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis-a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P = .009) and predicted the change in brain Aβ load (standardized β = 0.32, P = .004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P = .023). Discussion These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.
Collapse
Affiliation(s)
- Kunal Dhiman
- IMPACT - The Institute for Mental and Physical Health and Clinical Translation School of Medicine Deakin University Geelong Victoria Australia
- Western Health Partnership School of Nursing and Midwifery (Centre for Quality and Patient Safety Research in the Institute of Health Transformation) Faculty of Health Deakin University Melbourne Victoria Australia
- School of Medical and Health Sciences Edith Cowan University Joondalup Western Australia Australia
| | - Victor L Villemagne
- Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA
- Department of Molecular Imaging & Therapy and Centre for PET Austin Health Heidelberg Victoria Australia
- Department of Medicine The University of Melbourne Melbourne Victoria Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia
| | - Pierrick Bourgeat
- Australian e-Health Research Centre CSIRO Health and Biosecurity Brisbane Queensland Australia
| | - Qiao-Xin Li
- The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia
| | - Steven Collins
- Department of Medicine The University of Melbourne Melbourne Victoria Australia
- The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy and Centre for PET Austin Health Heidelberg Victoria Australia
- Department of Medicine The University of Melbourne Melbourne Victoria Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia
| | - David Ames
- National Ageing Research Institute Parkville Victoria Australia
- Academic Unit for Psychiatry of Old age St. George's Hospital The University of Melbourne Melbourne Victoria Australia
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden
- Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Gothenburg Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden
- Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Gothenburg Sweden
- Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK
- UK Dementia Research Institute at UCL London UK
- Hong Kong Center for Neurodegenerative Diseases Hong Kong China
| | - Ralph N Martins
- School of Medical and Health Sciences Edith Cowan University Joondalup Western Australia Australia
- Australian Alzheimer's Research Foundation Ralph and Patricia Sarich Neuroscience Research Institute Nedlands Western Australia Australia
- Department of Biomedical Sciences Macquarie University Sydney New South Wales Australia
- School of Psychiatry and Clinical Neurosciences University of Western Australia Perth Western Australia Australia
- KaRa Institute of Neurological Diseases Sydney New South Wales Australia
- Co-operative Research Centre for Mental Health Carlton Victoria Australia
| | - Veer Gupta
- IMPACT - The Institute for Mental and Physical Health and Clinical Translation School of Medicine Deakin University Geelong Victoria Australia
- School of Medical and Health Sciences Edith Cowan University Joondalup Western Australia Australia
| |
Collapse
|
6
|
Fu Y, Wang ZT, Huang LY, Tan CC, Cao XP, Tan L. Heart fatty acid-binding protein is associated with phosphorylated tau and longitudinal cognitive changes. Front Aging Neurosci 2022; 14:1008780. [PMID: 36299612 PMCID: PMC9588952 DOI: 10.3389/fnagi.2022.1008780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 09/21/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundPerturbation of lipid metabolism is associated with Alzheimer’s disease (AD). Heart fatty acid-binding protein (HFABP) is an adipokine playing an important role in lipid metabolism regulation.Materials and methodsTwo datasets separately enrolled 303 and 197 participants. First, we examine the associations of cerebrospinal fluid (CSF) HFABP levels with cognitive measures [including Mini-Mental State Examination (MMSE), Clinical Dementia Rating sum of boxes (CDRSB), and the cognitive section of Alzheimer’s Disease Assessment Scale] and AD biomarkers (CSF amyloid beta and tau levels). Second, we examine the longitudinal associations of baseline CSF HFABP levels and the variability of HFABP with cognitive measures and AD biomarkers. Structural equation models explored the mediation effects of AD pathologies on cognition.ResultsWe found a significant relationship between CSF HFABP level and P-tau (dataset 1: β = 2.04, p < 0.001; dataset 2: β = 1.51, p < 0.001). We found significant associations of CSF HFABP with longitudinal cognitive measures (dataset 1: ADAS13, β = 0.09, p = 0.008; CDRSB, β = 0.10, p = 0.003; MMSE, β = −0.15, p < 0.001; dataset 2: ADAS13, β = 0.07, p = 0.004; CDRSB, β = 0.07, p = 0.005; MMSE, β = −0.09, p < 0.001) in longitudinal analysis. The variability of HFABP was associated with CSF P-tau (dataset 2: β = 3.62, p = 0.003). Structural equation modeling indicated that tau pathology mediated the relationship between HFABP and cognition.ConclusionOur findings demonstrated that HFABP was significantly associated with longitudinal cognitive changes, which might be partially mediated by tau pathology.
Collapse
Affiliation(s)
- Yan Fu
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| | - Zuo-Teng Wang
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
- *Correspondence: Zuo-Teng Wang,
| | - Liang-Yu Huang
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| | - Chen-Chen Tan
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| | - Xi-Peng Cao
- Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| | - Lan Tan
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
- Lan Tan,
| |
Collapse
|